Literature DB >> 2486539

Glomerular structures and lipids in progressive renal disease.

J F Moorhead1, D C Wheeler, Z Varghese.   

Abstract

In the last few years, remarkable advances have been made in the understanding of lipoprotein metabolism in the pathogenesis of renal disease in animal models and in vitro cell culture. Central to this work is the problem of the progression of renal disease in humans. This review recapitulates the theory (Lancet 1982; II: 1309-1312) that the progression of disease depends in part on the damage inflicted on the glomerulus by lipoproteins. The glomerular environment of high or low pressure, basement membrane damage, and destruction or damage of the mesangial and epithelial cells permits the filtration of protein, the consequence of which is hyperlipidemia. Whatever the therapeutic measures employed, if proteinuria persists, hyperlipidemia will follow. This suggest that lipoprotein toxicity may contribute to the final common path of renal damage in progressive renal disease. "Lipoprotein toxicity" in arteries is called atherosclerosis, but this term ignores the complexity of the glomerulus and the possible tubular damage that might be caused by filtered lipoprotein. It is clear there is insufficient knowledge of the metabolism of the damaged kidney to confidently attribute the pathology of progression of disease to any single process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2486539

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  Nutritional management of chronic renal disease.

Authors:  S H Zlotkin
Journal:  CMAJ       Date:  1991-11-01       Impact factor: 8.262

2.  Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.

Authors:  Piero Ruggenenti; Annalisa Perna; Marcello Tonelli; Giacomina Loriga; Nicola Motterlini; Nadia Rubis; Franca Ledda; Stefano Rota; Andrea Satta; Antonio Granata; Giovanni Battaglia; Francesco Cambareri; Salvatore David; Flavio Gaspari; Nadia Stucchi; Sergio Carminati; Bogdan Ene-Iordache; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

3.  Should a 4-year-old girl with steroid-resistant nephrotic syndrome, hypercholesterolaemia and hypertriglyceridaemia be treated with lipid-lowering agents?

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

4.  Application of GC/MS-based metabonomic profiling in studying the lipid-regulating effects of Ginkgo biloba extract on diet-induced hyperlipidemia in rats.

Authors:  Qi Zhang; Guang-ji Wang; Ji-ye A; Di Wu; Ling-ling Zhu; Bo Ma; Yu Du
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

5.  A case of homozygous familial hypercholesterolemia with focal segmental glomerulosclerosis.

Authors:  Ahmet Midhat Elmaci; Harun Peru; Fatih Akin; Zuhal Akcoren; Melda Caglar; Ahmet Ozel
Journal:  Pediatr Nephrol       Date:  2007-07-17       Impact factor: 3.714

Review 6.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

7.  Association of gut microbiota with idiopathic membranous nephropathy.

Authors:  Mengfei Li; Lixue Wei; Jing Sun; Qianshen Zhu; He Yang; Yu Zhang; Chao Zhang; Lin Xi; Rong Zhao; Xuanyi Du
Journal:  BMC Nephrol       Date:  2022-04-30       Impact factor: 2.585

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.